MedTrace Logo

Biomarker Guided Therapies in Stage A/B Heart Failure

NCT02230891 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-10-21

Study results available
· View outcomes & findings →

Summary

Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at higher HF risk to see if the investigators can stabilize or improve ultrasound measures known to be associated with HF risk. This study will enroll only Veterans.

Conditions

Interventions

DRUG

Carvedilol

Carvedilol is a non selective beta blocker

DRUG

Spironolactone

Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure

OTHER

Usual care

standard care as per primary care provider

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Vijay Nambi, MBBS · Michael E. DeBakey VA Medical Center, Houston, TX

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-01
Primary Completion
2020-12-15
Completion
2020-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02230891 on ClinicalTrials.gov